Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	23.38	39.55	298.17	89.96	81.47	58.06
Short-Term Investments	67.98	62.88	29.31	83.51	211.47	222.77
Cash & Short-Term Investments	91.36	102.43	327.48	173.47	292.94	280.83
Cash Growth	-31.82%	-68.72%	88.79%	-40.79%	4.31%	-44.42%
Accounts Receivable	16.85	17.47	16.79	14.07	15.87	22
Other Receivables	-	-	-	-	53.8	28.57
Receivables	16.85	17.47	16.79	14.07	69.67	50.57
Prepaid Expenses	8.27	13.64	9.2	18.81	30.73	7.09
Other Current Assets	-	-	-	43.53	-	-
Total Current Assets	116.48	133.54	353.46	249.87	393.34	338.49
Property, Plant & Equipment	37.12	45.36	52	53.35	59.68	59.25
Long-Term Investments	-	-	-	-	12.75	4.99
Other Long-Term Assets	202.5	203.1	201.94	71.6	3.28	6.11
Total Assets	356.11	382	607.4	374.82	469.06	408.83
Accounts Payable	1.45	1.52	1.55	3.1	6.78	4.76
Accrued Expenses	11.3	12.83	20.41	37.95	76.07	57.76
Current Portion of Long-Term Debt	-	-	-	16.94	19.33	9.85
Current Portion of Leases	4.2	3.92	6.75	0.5	9.87	7.76
Current Unearned Revenue	-	-	-	0.1	11.52	31.58
Other Current Liabilities	6.49	6.49	-	-	-	-
Total Current Liabilities	23.44	24.77	28.72	58.59	123.57	111.7
Long-Term Debt	-	-	-	599.39	599.84	445.19
Long-Term Leases	40.79	45.24	45.41	52.68	47.22	47.73
Long-Term Unearned Revenue	-	-	0.19	0.31	0.35	6.76
Other Long-Term Liabilities	106.23	99	91.29	2.42	1.83	21.29
Total Liabilities	170.45	169	165.6	713.39	772.81	632.67
Common Stock	-	-	0	0	0	0
Additional Paid-In Capital	1,136	1,122	1,296	1,387	1,223	1,025
Retained Earnings	-950	-909.1	-853.91	-1,726	-1,527	-1,249
Comprehensive Income & Other	0.05	-0.07	-0.02	-	0.05	0.15
Shareholders' Equity	185.65	213	441.8	-338.57	-303.75	-223.84
Total Liabilities & Equity	356.11	382	607.4	374.82	469.06	408.83
Total Debt	44.98	49.16	52.16	669.52	676.26	510.53
Net Cash (Debt)	46.38	53.27	275.32	-496.05	-383.32	-224.71
Net Cash Growth	-44.24%	-80.65%	-	-	-	-
Net Cash Per Share	0.95	0.96	3.74	-7.14	-6.15	-4.04
Filing Date Shares Outstanding	49.17	48.16	62.86	74.7	64.33	62.52
Total Common Shares Outstanding	49.17	48.09	65.23	74.44	64.33	57.02
Working Capital	93.05	108.77	324.75	191.28	269.77	226.79
Book Value Per Share	3.78	4.43	6.77	-4.55	-4.72	-3.93
Tangible Book Value	185.65	213	441.8	-338.57	-303.75	-223.84
Tangible Book Value Per Share	3.78	4.43	6.77	-4.55	-4.72	-3.93
Machinery	-	3.68	19.04	26.03	35.88	36.33
Leasehold Improvements	-	26.21	24.58	24.05	24.28	22.16

Source: S&P Capital IQ. Standard template. Financial Sources.